JusticeItaly Official institution

Italy changes marketing permission for several buprenorphine medicines

Italy's medicines agency AIFA published a notice on 7 November 2026 announcing changes to the marketing permission for several human medicines that contain buprenorphine, an opioid painkiller. The excerpt does not say which products or companies are affected or what exactly is changing. The full details are in the official notice under reference 26A05800.

This summary was generated by AI; the official source prevails.

What does it mean?

Italy's medicine regulator has changed the official sales permission for some medicines that contain buprenorphine, a strong painkiller. If you use one of these products, the exact change is set out in the regulator's notice.

Who is affected?

Patients using buprenorphine-based medicines in Italy, and the companies that sell them.